OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
SAN DIEGO, May 04, 2017 -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Apricus’ first quarter 2017 financial results will be released on Thursday, May 11, 2017 at 4:01 p.m. Eastern Time. Company management will host a conference call on Thursday, May 11, 2017, at 4:30 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.
To participate by telephone, please dial (855) 780-7196 (Domestic) or (631) 485-4867 (International). The conference ID number is 18008306. The live audio webcast can be accessed via the Investor Relations’ section of Apricus’ website at www.apricusbio.com. Please log in approximately 5-10 minutes before the event to ensure a timely connection. The archived webcast will remain available for 30 days following the live call.
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus has two product candidates currently in development. Vitaros is a product candidate in the United States for the treatment of erectile dysfunction, which is in-licensed from Warner Chilcott Company, Inc., now a subsidiary of Allergan plc (Allergan). RayVa is our product candidate in Phase 2 development for the treatment of the circulatory disorder Raynaud’s phenomenon, secondary to scleroderma, for which Apricus owns worldwide rights.
For further information on Apricus, visit http://www.apricusbio.com.
Vitaros™ is Apricus’ trademark in the United States, which is pending registration and subject to the agreement with Allergan. Vitaros® is a registered trademark of Ferring International Center S.A. in certain countries outside of the United States. RayVa™ is Apricus’ trademark, which is registered in certain countries throughout the world and pending registration in the United States.
CONTACT: Institutional / Retail Investors: Matthew Beck [email protected] The Trout Group LLC (646) 378-2933
